MedPath

Dronabinol

Generic Name
Dronabinol
Brand Names
Marinol, Sativex, Syndros
Drug Type
Small Molecule
Chemical Formula
C21H30O2
CAS Number
1972-08-3
Unique Ingredient Identifier
7J8897W37S
Background

Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments .

Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are found throughout the body . While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms like Dronabinol or Nabilone), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers.

From a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body . The endocannabinoid system is widely distributed throughout the central and peripheral nervous system (via the Cannabinoid Receptors CB1 and CB2) and plays a role in many physiological processes such as inflammation, cardiovascular function, learning, pain, memory, stress and emotional regulation, and the sleep/wake cycle among many others . CB1 receptors are found in both the central and peripheral nervous system, and are most abundant in the hippocampus and amygdala, which are the areas of the brain responsible for short-term memory storage and emotional regulation. CB2 receptors are mainly located in the peripheral nervous system and can be found on lymphoid tissue where they are involved in regulation of immune function .

Indication

Dronabinol is indicated for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Associated Conditions
Anorexia, Chemotherapy-Induced Nausea and Vomiting

Effect of Cannabis on E-Cigarette Use Behavior

Phase 1
Recruiting
Conditions
Cannabis Use
Tobacco Use
Electronic Cigarette Use
Interventions
Drug: E-Cigarette Full Nicotine
Drug: E-Cigarette Placebo Nicotine
First Posted Date
2024-09-24
Last Posted Date
2025-04-02
Lead Sponsor
Johns Hopkins University
Target Recruit Count
100
Registration Number
NCT06609109
Locations
🇺🇸

Johns Hopkins University Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States

Effect of Cannabis on Cigarette Use Behavior

Phase 1
Recruiting
Conditions
Cannabis Use
Tobacco Use
Cigarette Smoking
Interventions
Drug: Cigarette Full Nicotine
Drug: Cigarette Reduced Nicotine
First Posted Date
2024-09-24
Last Posted Date
2025-01-24
Lead Sponsor
Johns Hopkins University
Target Recruit Count
100
Registration Number
NCT06609083
Locations
🇺🇸

Johns Hopkins University Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States

DRonabinol Treatment of OSA

Phase 1
Not yet recruiting
Conditions
Obstructive Sleep Apnea
Interventions
First Posted Date
2024-06-27
Last Posted Date
2025-05-07
Lead Sponsor
VA Office of Research and Development
Target Recruit Count
120
Registration Number
NCT06477952
Locations
🇺🇸

Jesse Brown VA Medical Center, Chicago, IL, Chicago, Illinois, United States

Dose-Response Characterization of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back Pain

Phase 2
Active, not recruiting
Conditions
Chronic Non-specific Low Back Pain
Interventions
Drug: Placebo
First Posted Date
2024-06-26
Last Posted Date
2025-05-20
Lead Sponsor
Vertanical GmbH
Target Recruit Count
652
Registration Number
NCT06475001
Locations
🇬🇧

St Pancras Clinical Research, London, United Kingdom

Reducing Breathlessness With Dronabinol in COPD Patients

Phase 3
Recruiting
Conditions
COPD
Cannabis
Breathlessness
Interventions
First Posted Date
2024-06-25
Last Posted Date
2025-03-28
Lead Sponsor
Vejle Hospital
Target Recruit Count
30
Registration Number
NCT06473701
Locations
🇩🇰

Vejle Hospital - A part of Lillebaelt Hospital, Vejle, Region Of Southern Denmark, Denmark

Effects of Drugs on Stress Memories

Early Phase 1
Recruiting
Conditions
Delta-9-tetrahydrocannabinol (THC)
Stress
Interventions
First Posted Date
2024-06-24
Last Posted Date
2024-07-09
Lead Sponsor
University of Chicago
Target Recruit Count
48
Registration Number
NCT06471647
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

Dronabinol as an Adjunct for Reducing Pain

Phase 2
Recruiting
Conditions
Low Back Pain
Back Injuries
Chronic Pain
Interventions
Drug: Placebo
First Posted Date
2024-06-12
Last Posted Date
2025-03-25
Lead Sponsor
Christopher D. Verrico
Target Recruit Count
75
Registration Number
NCT06454669
Locations
🇺🇸

Michael E Debakey VA Medical Center, Houston, Texas, United States

Effects of THC on Alcohol Consumption and Neural Correlates of Reward

Phase 2
Recruiting
Conditions
Cannabis Use Disorder
Interventions
First Posted Date
2024-06-06
Last Posted Date
2024-08-19
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
28
Registration Number
NCT06446479
Locations
🇺🇸

University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Warrior CARE: Cannabis Behavioral Health

Phase 1
Not yet recruiting
Conditions
Post Traumatic Stress Disorder
Cannabis Use
Suicide
Veterans
Marijuana
Interventions
First Posted Date
2024-04-24
Last Posted Date
2024-07-23
Lead Sponsor
Wayne State University
Target Recruit Count
500
Registration Number
NCT06381180
Locations
🇺🇸

Wayne State University, Detroit, Michigan, United States

Behavioral Pharmacology of Orally Administered THC and D-limonene

Phase 1
Recruiting
Conditions
Subjective Drug Effects
D-limonene
THC
Interventions
First Posted Date
2024-04-23
Last Posted Date
2025-05-16
Lead Sponsor
Johns Hopkins University
Target Recruit Count
65
Registration Number
NCT06378957
Locations
🇺🇸

Johns Hopkins Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath